EVNIN LUKE sold $13K of HOWL (indirect holdings)
EVNIN LUKE sold 27,698 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.46 on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure can influence short-term trading sentiment, but 10b5-1 plans are designed to reduce timing-based inference about future performance.
Market read
A director open-market sale under a 10b5-1 plan is typically a low-signal event; watch for any accompanying market reaction in HOWL’s tape after the filing.
What to watch
The filing does not disclose reasons for sale, and the indirect ownership structure may further dilute signal strength versus direct insider trades.
Background
SEC Form 4 reports an insider transaction for Werewolf Therapeutics, Inc. (HOWL). The director’s sale was executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Werewolf Therapeutics director EVNIN LUKE sold 27,698 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low-to-moderate downside pressure possible around the filing/rumor cycle; fundamental impact likely limited.
The filing is a disclosed sale (not a buy) but explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no stated sector/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderEVNIN LUKE
Director who sold 27,698 shares on 2026-05-28 under a 10b5-1 plan.